Bosutinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Bosutinib is an ofp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2012. Its mechanism of action is classified as Bcr-Abl Tyrosine Kinase Inhibitors. DrugCentral lists 205 molecular targets, including ABL1, MAP4K5 and LCK. Recorded indications include Blastic phase chronic myeloid leukemia, Chronic Myelocytic Leukemia Accelerated Phase and Chronic phase chronic myeloid leukemia.

• Approval status: ofp (first approved 2012 by the FDA).
• Drug class: Kinase Inhibitor.
• Mechanism of action: Bcr-Abl Tyrosine Kinase Inhibitors.
• Molecular targets: ABL1, MAP4K5, LCK and ERBB3 (205 listed in DrugCentral).
• Indications: Blastic phase chronic myeloid leukemia, Chronic Myelocytic Leukemia Accelerated Phase and Chronic phase chronic myeloid leukemia.
• ATC code: L01EA04 (BCR-ABL tyrosine kinase inhibitors).
• Molecular formula: C26H29Cl2N5O3; molecular weight 530.45 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Blastic phase chronic myeloid leukemia
• Chronic Myelocytic Leukemia Accelerated Phase
• Chronic phase chronic myeloid leukemia

Mechanism & targets

• Mechanism of action (MoA): Bcr-Abl Tyrosine Kinase Inhibitors
• Established pharmacologic class: Kinase Inhibitor

Molecular targets (205)

Target	Gene	Action	Activity
Tyrosine-protein kinase ABL1	ABL1	inhibitor	Kd 10.54
Mitogen-activated protein kinase kinase kinase kinase 5	MAP4K5	unknown	Kd 9.30
Tyrosine-protein kinase Lck	LCK	unknown	Kd 9.23
Receptor tyrosine-protein kinase erbB-3	ERBB3	unknown	Kd 9.11
Proto-oncogene tyrosine-protein kinase Src	SRC	inhibitor	Kd 9.00
Tyrosine-protein kinase ABL	ABL1|ABL2	unknown	IC50 8.96
Cyclin-G-associated kinase	GAK	unknown	Kd 8.89
Tyrosine-protein kinase FRK	FRK	unknown	Kd 8.85
Abelson tyrosine-protein kinase 2	ABL2	unknown	Kd 8.82
Serine/threonine-protein kinase 35	STK35	unknown	Kd 8.70
Mitogen-activated protein kinase kinase kinase kinase 2	MAP4K2	unknown	Kd 8.51
Misshapen-like kinase 1	MINK1	unknown	Kd 8.49
Tyrosine-protein kinase Blk	BLK	unknown	Kd 8.48
Tyrosine-protein kinase HCK	HCK	inhibitor	Kd 8.47
Tyrosine-protein kinase Yes	YES1	unknown	Kd 8.40
Tyrosine-protein kinase Lyn	LYN	inhibitor	Kd 8.38
STE20-like serine/threonine-protein kinase	SLK	unknown	Kd 8.33
Tyrosine-protein kinase BTK	BTK	unknown	Kd 8.32
Mitogen-activated protein kinase kinase kinase kinase 3	MAP4K3	unknown	Kd 8.29
Ephrin type-A receptor 3	EPHA3	unknown	Kd 8.24

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2014-09-26	PMDA	—	Pfizer Japan Inc	Yes
2012-09-04	FDA	—	WYETH PHARMS INC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01EA04	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › BCR-ABL tyrosine kinase inhibitors

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: ABL1, BCR · Testing Required
• FDA label: ABL1, BCR · Testing Required
• HCSC label: ABL1, BCR · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Diarrhoea	1646.8
Pleural effusion	596.5
Neoplasm progression	524.9
Nausea	354.2
Cytogenetic analysis abnormal	350.3
Philadelphia chromosome positive	236.9
Drug resistance	220.8
Second primary malignancy	165.2
Drug intolerance	143.1
Blast crisis in myelogenous leukaemia	141.4
Rash	134.7
Fatigue	121.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Bosutinib is on its molecule page.

• Molecular formula: C₂₆H₂₉Cl₂N₅O₃
• Molecular weight: 530.45 g/mol
• CAS number: 380843-75-4
• InChIKey: UBPYILGKFZZVDX-UHFFFAOYSA-N
• PubChem CID: 5328940

COC1=CC2=C(C=C1OCCCN1CCN(C)CC1)N=CC(C#N)=C2NC1=CC(OC)=C(Cl)C=C1Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Bosutinib used for?

DrugCentral lists the following indications for Bosutinib: Blastic phase chronic myeloid leukemia, Chronic Myelocytic Leukemia Accelerated Phase and Chronic phase chronic myeloid leukemia.

How does Bosutinib work?

Bosutinib is classified as Bcr-Abl Tyrosine Kinase Inhibitors; its molecular targets in DrugCentral include ABL1 (inhibitor), MAP4K5, LCK and ERBB3.

When was Bosutinib first approved?

Bosutinib was first approved by the FDA in 2012.

What drug class does Bosutinib belong to?

Bosutinib is in the Kinase Inhibitor class.

What is the chemical formula of Bosutinib?

Bosutinib has the molecular formula C26H29Cl2N5O3 and a molecular weight of 530.45 g/mol.

Sources

• DrugCentral drug card 4359 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL2095206 — compound record and bioactivity
• PubChem CID 5328940 — chemical identifiers
• DrugBank DB06616 — drug record
• FDA UNII 5018V4AEZ0 — substance identity
• DailyMed: FDA labels for Bosutinib — current prescribing information (label search)
• UniProt P00519 (ABL1) — target protein
• UniProt Q9Y4K4 (MAP4K5) — target protein
• UniProt P06239 (LCK) — target protein
• UniProt P21860 (ERBB3) — target protein
• UniProt P12931 (SRC) — target protein
• UniProt O14976 (GAK) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.